Endometrial cancer future or investigational therapies

Endometrial cancer Microchapters
Home
Patient Information
Overview
Historical perspective
Classification
Pathophysiology
Causes
Differentiating Endometrial cancer from other Diseases
Epidemiology and Demographics
Risk factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Endometrial cancer future or investigational therapies On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Endometrial cancer future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Endometrial cancer future or investigational therapies
CDC on Endometrial cancer future or investigational therapies
Endometrial cancer future or investigational therapies in the news
Blogs on Endometrial cancer future or investigational therapies
Directions to Hospitals Treating Endometrial cancer
Risk calculators and risk factors for Endometrial cancer future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shankar Kumar, M.B.B.S. [2]]

Future or Investigational Therapies

To minimize the complication of internal bleeding post lymph node dissection, sentinal node biopsy is being investigated for its usefulness in surgical staging. Even if it is found useful, clinicians have to understand the appropriate site for injecting the tracer and accurate mapping.

Though considerable data is lacking, it has been found that cytoreduction may be useful in women with intra-abdominal spread of cancer.